Reduced Cytokine Tumour Necrosis Factor by Pharmacological Intervention in a Preclinical Study

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2022 Jul 27

PMID 35883432

Authors

Armin Mooranian

Jacqueline Chester

Edan Johnston

Corina Mihaela Ionescu

Daniel Walker

Melissa Jones

Susbin Raj Wagle

Bozica Kovacevic

Thomas Foster

Momir Mikov

Hani Al-Salami

Affiliations

Soon will be listed here.

Abstract

Recent preclinical studies in our laboratory have shown that the bile acid profile is altered during diabetes development and such alteration has been linked to the diabetes-associated inflammatory profile. Hence, this study aimed to investigate if the first-line antidiabetic drug metformin will alter the bile acid profile and diabetes-associated inflammation in a murine model of pre-type 2 diabetes. C57 mice were randomly allocated into three equal groups of eight. Group One was given a low-fat diet (LFD), Group Two was given a high-fat diet (HFD), and Group Three was given an HFD and, upon prediabetes confirmation, daily oral metformin for one month. Blood glucose, glycated haemoglobin, drug concentrations in tissues and faeces, and the inflammatory and bile acid profiles were measured. Metformin showed wide tissue distribution and was also present in faeces. The bile acid profile showed significant alteration due to prediabetes, and although metformin did not completely normalize it, it did exert significant effects on both the bile acid and the inflammatory profiles, suggesting a direct and, to some extent, positive impact, particularly on the diabetes-associated inflammatory profile.

References

Lee C, Chae S, Jo S, Jerng U, Bae S . The Relationship between the Gut Microbiome and Metformin as a Key for Treating Type 2 Diabetes Mellitus. Int J Mol Sci. 2021; 22(7). PMC: 8037857. DOI: 10.3390/ijms22073566. View

Straniero S, Laskar A, Savva C, Hardfeldt J, Angelin B, Rudling M . Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism. J Lipid Res. 2020; 61(4):480-491. PMC: 7112145. DOI: 10.1194/jlr.RA119000307. View

Ridlon J, Kang D, Hylemon P . Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2005; 47(2):241-59. DOI: 10.1194/jlr.R500013-JLR200. View

Wilcock C, Bailey C . Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994; 24(1):49-57. DOI: 10.3109/00498259409043220. View

Ferrell J, Chiang J . Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic Targets. Diabetes Metab J. 2019; 43(3):257-272. PMC: 6581552. DOI: 10.4093/dmj.2019.0043. View

Chen M, Takeda K, Sundrud M . Emerging roles of bile acids in mucosal immunity and inflammation. Mucosal Immunol. 2019; 12(4):851-861. DOI: 10.1038/s41385-019-0162-4. View

Gadaleta R, van Erpecum K, Oldenburg B, Willemsen E, Renooij W, Murzilli S . Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011; 60(4):463-72. DOI: 10.1136/gut.2010.212159. View

Mooranian A, Zamani N, Mikov M, Golocorbin-Kon S, Stojanovic G, Arfuso F . Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses. Artif Cells Nanomed Biotechnol. 2018; 46(sup3):S741-S747. DOI: 10.1080/21691401.2018.1511571. View

Wagle S, Kovacevic B, Walker D, Ionescu C, Jones M, Stojanovic G . Pharmacological and Advanced Cell Respiration Effects, Enhanced by Toxic Human-Bile Nano-Pharmaceuticals of Probucol Cell-Targeting Formulations. Pharmaceutics. 2020; 12(8). PMC: 7463437. DOI: 10.3390/pharmaceutics12080708. View

10.

Mamo J, Lam V, Brook E, Mooranian A, Al-Salami H, Fimognari N . Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet. Diab Vasc Dis Res. 2018; 16(1):87-97. DOI: 10.1177/1479164118795274. View

11.

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2019; 43(Suppl 1):S14-S31. DOI: 10.2337/dc20-S002. View

12.

Gedawy A, Al-Salami H, Dass C . Role of metformin in various pathologies: state-of-the-art microcapsules for improving its pharmacokinetics. Ther Deliv. 2020; 11(11):733-753. DOI: 10.4155/tde-2020-0102. View

13.

Mooranian A, Negrulj R, Takechi R, Mamo J, Al-Sallami H, Al-Salami H . The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Deliv Transl Res. 2018; 8(3):543-551. DOI: 10.1007/s13346-017-0473-5. View

14.

Atkinson M, Eisenbarth G, Michels A . Type 1 diabetes. Lancet. 2013; 383(9911):69-82. PMC: 4380133. DOI: 10.1016/S0140-6736(13)60591-7. View

15.

Scarpello J, Hodgson E, Howlett H . Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med. 1998; 15(8):651-6. DOI: 10.1002/(SICI)1096-9136(199808)15:8<651::AID-DIA628>3.0.CO;2-A. View

16.

Pavlidis P, Powell N, Vincent R, Ehrlich D, Bjarnason I, Hayee B . Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?. Aliment Pharmacol Ther. 2015; 42(7):802-17. DOI: 10.1111/apt.13333. View

17.

Woodhams L, Al-Salami H . The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus. Ther Deliv. 2017; 8(6):401-409. DOI: 10.4155/tde-2017-0010. View

18.

Labbe A, Ganopolsky J, Martoni C, Prakash S, Jones M . Bacterial bile metabolising gene abundance in Crohn's, ulcerative colitis and type 2 diabetes metagenomes. PLoS One. 2014; 9(12):e115175. PMC: 4269443. DOI: 10.1371/journal.pone.0115175. View

19.

Mikov M, danic M, Pavlovic N, Stanimirov B, Golocorbin-Kon S, Stankov K . Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics. Eur J Drug Metab Pharmacokinet. 2017; 43(3):269-280. DOI: 10.1007/s13318-017-0441-y. View

20.

Carter D, Howlett H, Wiernsperger N, Bailey C . Differential effects of metformin on bile salt absorption from the jejunum and ileum. Diabetes Obes Metab. 2003; 5(2):120-5. DOI: 10.1046/j.1463-1326.2003.00252.x. View